Clinical trials: Second-Line
Non-small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who…
- Trial name
- NCT06542731
- Testing
- ONO-4578, ONO-4538, Docetaxel
- Where
- 13 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Adult Hepatocellular Carcinoma
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worldwide and the third most common cause of death from cancer.
- Trial name
- G-202-003 (NCT01777594)
- Testing
- G-202
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GenSpera, Inc.
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
- Trial name
- NCT02605044
- Testing
- Masitinib (AB1010), FOLFIRI
- Where
- 3 sites in France, Singapore and 1 more
- Volunteers
- 123 people
- Sponsor
- AB Science
Advanced Hepatocellular Carcinoma (HCC)
A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301…
- Trial name
- NCT07540832
- Testing
- WGI-0301, Lenvatinb
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Lung Cancer
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small…
- Trial name
- NCT00054184
- Testing
- docetaxel, paclitaxel poliglumex
- Where
- 35 sites in United States
- Volunteers
- 350 people
- Sponsor
- CTI BioPharma
Non-small Cell Lung Cancer
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the…
- Trial name
- NCT06841055
- Testing
- Pumitamig, Docetaxel
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 60 people
- Sponsor
- BioNTech SE
Prostatic Neoplasms
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]
Primary objectives: To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting. Secondary objectives: To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as…
- Trial name
- NCT00268710
- Testing
- docetaxel
- Sponsor
- Sanofi
Cancer, Ovarian Cancer
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.
- Conditions
- Cancer, Ovarian Cancer, Solid Tumor
- Trial name
- NCT00753740
- Testing
- IT-101 (12mg/m2/dose), IT-101 (15mg/m2/dose)
- Where
- 7 sites in United States
- Sponsor
- NewLink Genetics Corporation
Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line…
- Trial name
- NCT01289041
- Testing
- BKM120
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Urothelial Cancer, Metastatic Urothelial Cancer
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
- Conditions
- Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Bladder Cancer (BC)
- Trial name
- NCT07869836
- Testing
- T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
- Where
- 2 sites in United States
- Volunteers
- 520 people
- Sponsor
- SystImmune Inc.
Non-small Cell Lung Cancer
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01792479
- Testing
- BIND-014
- Where
- 17 sites in United States, Russia
- Volunteers
- 64 people
- Sponsor
- BIND Therapeutics
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Metastatic Melanoma
A Study of Tasisulam in Treating Participants With Malignant Melanoma
The primary purpose of this study is to determine the objective response rate (complete and partial response) for participants who receive tasisulam after one prior systemic treatment for unresectable or metastatic melanoma.
- Trial name
- NCT00383292
- Testing
- tasisulam
- Where
- 13 sites in United States, Australia
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
This observational study will evaluate the safety and efficacy of Bevacizumab in combination with 5-Fluorouracil based chemotherapy as first-line and second-line therapy in Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT01319877
- Where
- 24 sites in China
- Volunteers
- 609 people
- Sponsor
- Hoffmann-La Roche
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
- Trial name
- NCT01101906
- Testing
- OSI-906
- Where
- 41 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
This randomized parallel group study will assess the efficacy and safety of erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or…
- Trial name
- NCT01204697
- Testing
- docetaxel, erlotinib [Tarceva]
- Where
- 20 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer, Neoplasms, Breast
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
- Trial name
- NCT00051103
- Testing
- Investigational Cancer Drug
- Where
- 30 sites in United States
- Sponsor
- GlaxoSmithKline